Search

• ViiV Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen

  Media

  First phase III studies to show efficacy of two-drug regimen as maintenance therapy

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-results-from-first-phase-iii-studies-of-two-drug-hiv-treatment-regimen/

  First published: 19 December 2016

• ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023

  Media

  Key data to be presented include long-term and real-world data, including long-acting and 2-drug regimens.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-23-abstracts-from-innovative-hiv-treatment-and-prevention-portfolio-at-eacs-2023/

  First published: 18 October 2023

• 

  Dr Tony Wood

  Innovation

  tbd

  https://www.gsk.com/en-gb/innovation/our-leading-scientists/tony-wood/

  First published: 18 September 2024

• 

  History and heritage

  Company

  It began when Plough Court Pharmacy was established in 1715. Discover GSK’s journey to the company we are today

  https://www.gsk.com/en-gb/company/history-and-heritage/

  First published: 27 February 2025

• ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV

  Media

  Long-acting regimen is based on co-administration of cabotegravir and rilpivirine injections once-monthly or once every 2-months ​

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-positive-chmp-opinion-for-long-acting-regimen-for-the-treatment-of-hiv/

  First published: 16 October 2020

• ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

  Media

  New treatment can enable people living with HIV to reduce the days they receive treatment from 365 to 12 or 6 per year

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-the-marketing-authorisation-of-the-first-complete-long-acting-injectable-hiv-treatment-in-europe/

  First published: 21 December 2020

• ViiV Healthcare continues to deliver long-acting injectable HIV innovation with late-breaking data and real-world insights across pipeline and portfolio at CROI 2025

  Media

  Real-world and implementation data highlight effectiveness of Cabenuva and Apretude.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-continues-to-deliver-long-acting-injectable-hiv-innovation-at-croi-2025/

  First published: 09 March 2025

• ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen Dovato (dolutegravir/lamivudine) alongside other key research advances at the HIV Glasgow 2020 congress

  Media

  Data presented will reinforce the potential to shift the treatment paradigm to 2-drug regimens (2DRs) for people living with HIV

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-long-term-safety-and-efficacy-data-for-2-drug-regimen/

  First published: 30 September 2020